1. Progression-free survival was 6.3 months for the amivantamab–chemotherapy group, 8.3 months for the amivantamab–lazertinib–chemotherapy group, and 4.2 months for the chemotherapy group. 2. Adverse events grade 3 or higher occurred in 72% vs 92% vs 48% respectively, with the most common adverse events being neutropenia, thrombocytopenia, anemia, and leukopenia Evidence Rating Level: 1 (Excellent)